Stock 2096 SIMCERE PHARMACEUTICAL GROUP LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Market Closed - Hong Kong S.E.
Other stock markets
 01:38:49 06/05/2024 pm IST 		5-day change 1st Jan Change
5.7 HKD +0.35% Intraday chart for Simcere Pharmaceutical Group Limited +7.55% -15.30%
25/04 Simcere Pharmaceutical’ Profit Down 23% in 2023 MT
10/04 Simcere Pharmaceutical's Cancer Drug Gets Fast Track Designation From US FDA MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
AQ
PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT
PR
Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
PR
Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue
PR
Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day
PR
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day
PR
Simcere Pharma (2096.HK) Announces a Positive Profit Alert
PR
Simcere Pharmaceutical : FURTHER ANNOUNCEMENT PROFIT FORECAST IN RELATION TO DISPOSAL OF SUBSIDIARIES
PU
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE ADDITION OF NEW INDICATIONS OF TRILACICLIB FOR INJECTION
PU
Simcere Pharmaceutical : CHANGE IN USE OF PROCEEDS
PU
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM-307 ISSUED BY THE CENTER FOR DRUG EVALUATION OF NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC
PU
Simcere Pharmaceutical : RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER
PU
Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee
PU
Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL OF PHASE III CLINICAL TRIAL APPLICATION FOR ADDITION OF NEW INDICATION FOR ENDOSTAR BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 2096 Stock
  4. News Simcere Pharmaceutical Group Limited
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW